By Nigam Arora
Guardant Health Inc. (GH), a cancer-detection company that The Arora Report recommended at an average price of $26.34, is trading at $161.26 as of this writing after jumping over 10% following the release of its second-quarter results, bringing the gain for members who followed the signal to approximately 512%.
The magnitude of the gain naturally attracts attention, but serious investors should not look at Guardant Health simply as a stock that happened to rise several hundred percent. The more important lesson is how an investor can identify a major change early, before the change becomes obvious to Wall Street, before the favorable narrative becomes widely accepted, and before a stock’s success is repeatedly discussed in the financial media.
That is what The Arora Report’s ZYX Change Method is designed to do. To learn about the six screens of the ZYX Change Method, please click here.
Guardant Health Reports Strong Revenue Growth And Raises Guidance
Guardant Health reported second-quarter revenue of $335 million, substantially ahead of the consensus estimate of approximately $314 million, while revenue increased 44% from the prior-year period.
The company also raised its full-year 2026 revenue outlook to a range of $1.34 billion to $1.36 billion, compared with its prior outlook of $1.30 billion to $1.32 billion and the consensus estimate of approximately $1.31 billion.
Guardant Health continues to expect a full-year non-GAAP gross margin of 64% to 65%, but it increased its non-GAAP operating expense outlook to a range of $1.08 billion to $1.10 billion from the prior range of $1.05 billion to $1.07 billion. The company also increased its expected free-cash-flow burn to $195 million to $205 million from its previous projection of $185 million to $195 million.
The higher spending and cash burn are important and should not be ignored, but investors also need to understand why they are increasing. According to the company, the revised outlook reflects accelerated investment in laboratory capacity to support rapid growth in Shield volume. Even after the increase, the projected cash burn represents an improvement from the $233 million Guardant Health reported for full-year 2025.
Guardant Health also reported an adjusted loss of 42 cents per share, compared with the consensus estimate of a 39-cent loss.
Why Revenue Matters More Than Earnings At This Stage
In The Arora Report analysis, investors should not place excessive emphasis on the quarterly earnings number at this point in Guardant Health’s development because the company is still in a phase in which rapid revenue growth, expanding test volumes, successful commercialization, reimbursement, regulatory progress and the ability to build the infrastructure required to serve a much larger market are more important than maximizing near-term earnings.
This does not mean that losses, operating expenses and cash burn do not matter. They matter a great deal, especially because companies that continually consume cash can eventually be forced to raise capital on unfavorable terms. However, when a company is addressing a large market and its products are gaining meaningful adoption, an increase in spending can be constructive when the spending is directed toward supporting demand that is already materializing.
The distinction investors need to make is between a company spending more because its business model is not working and a company spending more because growth is occurring faster than previously expected. Guardant Health’s raised revenue guidance, 44% year-over-year revenue growth and investment in laboratory capacity to support Shield volumes indicate that the present increase in spending is connected to expansion, although investors should continue to closely monitor cash burn, gross margins and the pace at which increased revenue ultimately produces operating leverage.
The company stated that growth was broad-based across its portfolio, with strong oncology volumes and acceleration across every product. Guardant Health also highlighted the FDA approval of Guardant360 Liquid CDx, which strengthens its portfolio and may support sustained growth over the coming years.
Why The Arora Report Recommended GH When It Was Still Near $26
By the time most investors become excited about a stock, a substantial portion of the opportunity has often already passed because the favorable story has become well known, Wall Street analysts have raised their targets, the financial media has begun repeating the bullish narrative and investors who bought earlier are sitting on large gains.
The Arora Report does not seek to wait for universal agreement before acting. The objective is to identify important change while it is still in its early stages and while the probabilities are beginning to shift, but before the shift is fully reflected in the stock price.
The ZYX Change Method is based on the premise that money is made in the markets when investors correctly identify change before the crowd, whether that change is occurring in technology, consumer behavior, regulation, medical practice, capital spending, competitive positioning, management execution, institutional flows or investor psychology.
In the case of Guardant Health, the opportunity was not based on a single earnings report or a sudden surge in enthusiasm for cancer-detection stocks. The opportunity developed from the possibility that advances in liquid biopsy, precision oncology and blood-based cancer screening could materially change how cancer is detected, monitored and treated.
When The Arora Report recommended GH at an average price of $26.34, the favorable outcome that investors now see in the stock price was far from certain. There were meaningful questions about commercialization, reimbursement, competition, regulatory execution, cash burn and whether Guardant Health could translate the scientific promise of its technology into a sufficiently large and durable business.
Those risks did not disappear simply because The Arora Report recommended the stock. Successful investing does not require pretending that risks do not exist. It requires determining whether the potential reward is sufficiently large relative to the risks, whether the probabilities are moving in the right direction, and whether the position size is appropriate for the uncertainty.
GH Was Identified In The First Stage Of The Trade
The Arora Report’s framework recognizes five stages of a trade. To learn about the five stages of a long trade, please click here. The greatest potential rewards are often available in the first stage, when a major change is beginning but has not yet been broadly recognized.
The first stage is also the most difficult because investors do not have the psychological comfort that comes from widespread agreement. The headlines may still be negative, the historical financial statements may not yet reflect the future opportunity, and many Wall Street analysts may remain focused on the company’s existing limitations rather than the change that could alter its trajectory.
By the later stages, the company may have already demonstrated substantial growth, analysts may have become enthusiastic, institutional investors may have accumulated large positions and the stock may have appreciated significantly. At that point, the investment may appear safer because the story is more widely accepted, but the risk-reward may be considerably less attractive because the investor is paying a much higher price for that increased certainty.
The Arora Report identified Guardant Health in the first stage of the trade, when the potential change was visible but had not yet been fully recognized or priced into the stock. The subsequent gain of approximately 512% demonstrates the potential advantage of identifying change early, but it is equally important to recognize that not every first-stage opportunity will succeed, which is why rigorous analysis, disciplined position sizing and risk control are essential parts of the process.
Should Investors Buy GH After A 512% Gain?
Investors who already own GH may consider continuing to hold the stock without a target at this time.
The absence of a target does not mean the stock should be held regardless of what happens. It means that attempting to impose an arbitrary price objective on a rapidly evolving growth company may cause investors to sell prematurely when the underlying fundamentals and momentum remain favorable.
At the same time, investors who do not already own GH should not assume that a strong earnings report and a 10% aftermarket jump automatically create an attractive entry point. Chasing a stock after a major gain can expose an investor to poor risk-reward, even when the company’s long-term prospects remain attractive.
Those who are not in GH may consider waiting for a new signal. A new signal would take into account the stock’s price, momentum, investor positioning, broader market conditions, upcoming catalysts and the latest fundamental developments rather than relying only on the fact that the company has reported strong revenue growth.
The Real Lesson From The 512% Gain
It is tempting to look at a gain of 512% and conclude that the lesson is simply to find another cancer-detection company. That is not the lesson.
The lesson is that large gains often develop when investors identify a consequential change early, understand why the change matters, take an appropriately sized position while uncertainty is still high, and then remain patient enough to allow the thesis to develop.
Most investors do the opposite. They wait until a company has already produced exceptional results, the stock has already risen sharply and the bullish case has become comfortable and widely accepted. They then buy because the historical performance gives them confidence, even though the future risk-reward may no longer resemble the opportunity that existed at the beginning of the move.
The purpose of the ZYX Change Method is to improve the odds of getting ahead of the crowd rather than following it.
Investors can learn more about the ZYX Change Method and the five stages of a trade at TheAroraReport.com.
Do Not Miss The Next Early-Stage Opportunity
Blog readers are seeing the Guardant Health result after the stock has already produced a gain of approximately 512%, but members of ZYX Buy received the signal when GH was still in the first stage of the trade.
The distinction is important. Reading about a successful investment after the gain has occurred may be educational, but receiving the analysis and signal while the opportunity is still developing is what gives an investor the ability to act.
There will be other opportunities. There may also be another attractive opportunity to buy GH if the stock provides a favorable entry point, but investors who are not receiving the signals in real time may once again learn about the opportunity only after a significant portion of the move has already occurred.
Investors who want to receive future ZYX Buy signals, including a potential new signal on GH when warranted by the probabilities, may start a free 30-day trial of ZYX Buy.
The credit card is not charged during the 30-day trial, allowing investors to evaluate the service, review the analysis and experience the disciplined process used by The Arora Report before making a financial commitment.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 1% of the content from our paid services. …TO RECEIVE REMAINING 99%, INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES AND SIGNALS IN REAL TIME, TAKE A FREE
TRIAL TO PAID SERVICES.
The Arora Report is one of the only major global investment newsletters that does not employ a single salesperson—because it does not need to. While competitors rely on high-pressure sales tactics, The Arora Report grows purely through results, with satisfied members recommending it to their family and friends.
Join the service that investors trust the most and recommend to family and friends.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
